FDMT. – 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc.FDMT
$3.27Name : 4D Molecular Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $151,481,440.00
EPSttm : -3.18
4D Molecular Therapeutics, Inc.
$3.27
1.51%$0.05Float Short %
12.69
Margin Of Safety %
Put/Call OI Ratio
0.22
EPS Next Q Diff
-0.03
EPS Last/This Y
-0.59
EPS This/Next Y
-0.4
Price
3.27
Target Price
32.4
Analyst Recom
1.75
Performance Q
-28.6
Relative Volume
0.69
Beta
2.82
Ticker: FDMT
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | FDMT | 2.77 | 0.10 | 0.02 | 5916 |
| 2025-04-15 | FDMT | 3.1 | 0.10 | 0.01 | 5964 |
| 2025-04-16 | FDMT | 2.91 | 0.10 | 17.33 | 6110 |
| 2025-04-17 | FDMT | 3.05 | 0.21 | 0.19 | 6780 |
| 2025-04-18 | FDMT | 3.06 | 0.21 | 0.16 | 6780 |
| 2025-04-21 | FDMT | 3.09 | 0.09 | 0.05 | 4000 |
| 2025-04-22 | FDMT | 3.39 | 0.09 | 1.36 | 4013 |
| 2025-04-23 | FDMT | 3.41 | 0.10 | 0.23 | 4084 |
| 2025-04-24 | FDMT | 3.25 | 0.15 | 0.00 | 3721 |
| 2025-04-25 | FDMT | 3.34 | 0.15089121081746 | 999.99 | 3745 |
| 2025-04-28 | FDMT | 3.34 | 0.15119852489244 | 5.5 | 3746 |
| 2025-04-29 | FDMT | 3.23 | 0.15 | 0.00 | 3731 |
| 2025-04-30 | FDMT | 3.37 | 0.15 | 0.38 | 3733 |
| 2025-05-01 | FDMT | 3.43 | 0.15 | 0.38 | 3733 |
| 2025-05-02 | FDMT | 3.76 | 0.15 | 0.00 | 3726 |
| 2025-05-05 | FDMT | 3.56 | 0.15 | 0.00 | 3680 |
| 2025-05-06 | FDMT | 3.08 | 0.15 | 10.44 | 3681 |
| 2025-05-07 | FDMT | 3.12 | 0.22 | 0.00 | 3937 |
| 2025-05-08 | FDMT | 3.23 | 0.22 | 0.00 | 3937 |
| 2025-05-09 | FDMT | 3.09 | 0.22 | 0.00 | 3967 |
| 2025-05-12 | FDMT | 3.31 | 0.22 | 0.00 | 3959 |
| 2025-05-13 | FDMT | 3.26 | 0.22 | 0.00 | 3988 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | FDMT | 2.78 | -30.4 | - | -3.57 |
| 2025-04-15 | FDMT | 3.10 | -30.4 | - | -3.57 |
| 2025-04-16 | FDMT | 2.91 | -30.4 | - | -3.57 |
| 2025-04-17 | FDMT | 3.06 | -30.4 | - | -3.57 |
| 2025-04-18 | FDMT | 3.06 | -30.4 | - | -3.57 |
| 2025-04-21 | FDMT | 3.09 | -30.6 | - | -3.57 |
| 2025-04-22 | FDMT | 3.40 | -30.6 | - | -3.57 |
| 2025-04-23 | FDMT | 3.42 | -30.6 | - | -3.57 |
| 2025-04-24 | FDMT | 3.25 | -30.6 | - | -3.57 |
| 2025-04-25 | FDMT | 3.34 | -30.6 | - | -3.57 |
| 2025-04-28 | FDMT | 3.34 | -30.6 | - | -3.57 |
| 2025-04-29 | FDMT | 3.24 | -30.6 | - | -3.57 |
| 2025-04-30 | FDMT | 3.37 | -30.6 | - | -3.57 |
| 2025-05-01 | FDMT | 3.43 | -30.6 | - | -3.57 |
| 2025-05-02 | FDMT | 3.76 | -30.6 | - | -3.57 |
| 2025-05-05 | FDMT | 3.57 | -30.6 | - | -3.57 |
| 2025-05-06 | FDMT | 3.09 | -30.6 | - | -3.57 |
| 2025-05-07 | FDMT | 3.12 | -30.6 | - | -3.57 |
| 2025-05-08 | FDMT | 3.24 | -30.6 | - | -3.57 |
| 2025-05-09 | FDMT | 3.08 | -30.6 | - | -3.57 |
| 2025-05-12 | FDMT | 3.32 | -30.6 | - | -3.57 |
| 2025-05-13 | FDMT | 3.27 | -30.6 | - | -3.57 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | FDMT | 0.00 | -23.65 | 12.76 |
| 2025-04-15 | FDMT | 0.00 | -23.65 | 12.76 |
| 2025-04-16 | FDMT | 0.00 | -23.65 | 12.76 |
| 2025-04-17 | FDMT | 0.00 | -23.65 | 12.76 |
| 2025-04-18 | FDMT | 0.00 | -23.65 | 12.76 |
| 2025-04-21 | FDMT | 0.00 | -22.14 | 12.76 |
| 2025-04-22 | FDMT | 0.00 | -22.14 | 12.76 |
| 2025-04-23 | FDMT | 0.00 | -22.14 | 12.76 |
| 2025-04-24 | FDMT | 0.00 | -22.14 | 12.76 |
| 2025-04-25 | FDMT | 0.00 | -22.14 | 12.76 |
| 2025-04-28 | FDMT | 0.00 | -24.59 | 13.12 |
| 2025-04-29 | FDMT | 0.00 | -24.59 | 13.12 |
| 2025-04-30 | FDMT | 0.00 | -24.59 | 13.12 |
| 2025-05-01 | FDMT | 0.00 | -24.59 | 13.12 |
| 2025-05-02 | FDMT | 0.00 | -24.59 | 13.12 |
| 2025-05-05 | FDMT | 0.00 | -25.67 | 13.12 |
| 2025-05-06 | FDMT | 0.00 | -25.67 | 13.12 |
| 2025-05-07 | FDMT | 0.00 | -25.67 | 13.12 |
| 2025-05-08 | FDMT | 0.00 | -25.67 | 13.12 |
| 2025-05-09 | FDMT | 0.00 | -25.67 | 13.12 |
| 2025-05-12 | FDMT | 0.00 | -24.30 | 12.69 |
| 2025-05-13 | FDMT | 0.00 | -24.30 | 12.69 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.86
Avg. EPS Est. Current Quarter
-0.86
Avg. EPS Est. Next Quarter
-0.89
Insider Transactions
Institutional Transactions
-24.3
Beta
2.82
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
21
Growth Score
26
Sentiment Score
29
Actual DrawDown %
94.1
Max Drawdown 5-Year %
Target Price
32.4
P/E
Forward P/E
PEG
P/S
7574.19
P/B
0.32
P/Free Cash Flow
EPS
-3.37
Average EPS Est. Cur. Y
-3.57
EPS Next Y. (Est.)
-3.97
Target Price Estimates Raised
Target Price Estimates Lowered
2
Profit Margin
-767126.09
Relative Volume
0.69
Return on Equity vs Sector %
-61.2
Return on Equity vs Industry %
-44.3
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
4D Molecular Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 227
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading